OBJECTIVES: To study patient's out-of-pocket expenditures in patients taking oral oncology medication for the treatment of Multiple Myeloma who are enrolled in a specialty pharmacy program.  METHODS: A retrospective analysis of pharmacy claims and reimbursement data for oncology patients enrolled in a specialty pharmacy program and receiving biologic drugs from January 1, 2013 through October 31, 2013 was conducted.  Patients with a primary diagnosis of Multiple Myeloma (ICD-9 CM: 203.xx) prescription data were included. There were no exclusion criteria. The distribution of out-of-pocket patient's costs per prescription were performed comparing average co-pay responsibility per prescription after insurance to average patient co-pay per prescription after funding assistance.  RESULTS: A total of 22,566 prescriptions were included. The average patient co-pay responsibility after insurance was $435.00 per prescription and the average patient co-pay after funding assistance was $81.00 per prescription. This resulted in 12,822 (91.17%) of the prescriptions had a patient co-pay of under $10.00 after funding assistance. The patient’s insurance type was as follows: private insurance was 59%, Medicare was 25%, Pharmacy Benefit Manager was 10%, Tricare was 1%, and Medicaid was 5%. CONCLUSIONS: In this retrospective analysis of pharmacy and financial claims data, Multiple Myeloma patients significantly reduced their out-of-pocket expenditures, from an average of $435.00 to $81.00 by the specialty pharmacy gaining funding assistance for the patient.